Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2015 1
2018 1
2021 2
2022 4
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed.
Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, Vormoor HJ, Calkoen FG, Locatelli F, Del Bufalo F, Rives S, Jacoby E, Balduzzi A, Bourquin JP, Baruchel A. Rossig C, et al. Among authors: calkoen fg. J Clin Oncol. 2024 Jan 20;42(3):253-257. doi: 10.1200/JCO.23.01314. Epub 2023 Nov 27. J Clin Oncol. 2024. PMID: 38011605 No abstract available.
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, O'Brien MM, Rubinstein JD, Kalwak K, De Moerloose B, Jacoby E, Bader P, López-Duarte M, Goemans BF, Locatelli F, Hoogerbrugge P, Calkoen FG, Zwaan CM. Ceolin V, et al. Among authors: calkoen fg. Leukemia. 2023 Jan;37(1):53-60. doi: 10.1038/s41375-022-01740-9. Epub 2022 Oct 30. Leukemia. 2023. PMID: 36310183
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Dekker L, Calkoen FG, Jiang Y, Blok H, Veldkamp SR, De Koning C, Spoon M, Admiraal R, Hoogerbrugge P, Vormoor B, Vormoor HJ, Visscher H, Bierings M, Van Der Vlugt M, Van Tinteren H, Nijstad AL, Huitema ADR, Van Der Elst KCM, Pieters R, Lindemans CA, Nierkens S. Dekker L, et al. Among authors: calkoen fg. Blood Adv. 2022 Apr 12;6(7):1969-1976. doi: 10.1182/bloodadvances.2021006700. Blood Adv. 2022. PMID: 35134115 Free PMC article.
SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
McNerney KO, Richards RM, Aguayo-Hiraldo P, Calkoen FG, Talano JA, Moskop A, Balduzzi A, Krajewski J, Dave H, Vatsayan A, Callahan C, Liu H, Li Y, Davis KL, Maude SL. McNerney KO, et al. Among authors: calkoen fg. J Immunother Cancer. 2023 Jan;11(1):e005957. doi: 10.1136/jitc-2022-005957. J Immunother Cancer. 2023. PMID: 36707090 Free PMC article.
The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles.
Vazaios K, Stavrakaki Ε, Vogelezang LB, Ju J, Waranecki P, Metselaar DS, Meel MH, Kemp V, van den Hoogen BG, Hoeben RC, Chiocca EA, Goins WF, Stubbs A, Li Y, Alonso MM, Calkoen FG, Hulleman E, van der Lugt J, Lamfers MLM. Vazaios K, et al. Among authors: calkoen fg. Mol Ther Oncol. 2024 Apr 15;32(2):200804. doi: 10.1016/j.omton.2024.200804. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38694569 Free PMC article.
14 results